Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2011

View Archived Issues

Sanofi discloses novel agents for diabetic foot ulcers

Novel Novartis product enters phase I/II trial in healthy subjects and patients with diabetes

Roche discovers new phosphodiesterase 10A inhibitors

New histone deacetylase 9 inhibitors claimed

Novel B-raf inhibitors patented by Selexagen

NCCU patents new beta-nerve growth factor enhancers

FDA clears Newron to conduct first-in-human study of add-on therapy for schizophrenia

U.S. Department of Defense funds development of NeoStem stem cell technology for osteoporosis

New urine-based biomarker test predicts risk of prostate cancer in men with elevated PSA

GSK submits sNDA in U.S. for use of Horizant

Pluristem's agreement with United Therapeutics for PLX cells is effective

Amarin reaches SPA agreement with FDA for phase III REDUCE-IT trial

Array BioPharma and Genentech enter agreement for Chk1 program

NCI to sponsor clinical trials of Pharmacyclics BTK inhibitor

Ironwood Pharmaceuticals and Forest Laboratories submit linaclotide NDA for two indications

Novel injectable coacervate induces angiogenesis in vivo

Enobia raises funds for development of ENB-0040

Chugai files application for additional indication for Kytril in Japan

ThromboGenics expects ocriplasmin filings in U.S. and E.U. before year-end

Adventrx receives FDA complete response letter for Exelbine

New phase I trial of anticancer drug TKM-PLK1 cleared by FDA

Glenmark Pharmaceuticals initiates global phase IIb trials of revamilast

GWAS identifies new lung cancer susceptibility loci in Chinese population

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...